Makes no sense to use (and at what cost) another companies test and system, when we are supposed to be developing ours, unless it's purely to develop a market.
It's all very well having these 'investor presentations' but currently they aren't explaining any kind of coherent plan going forward.
If FebriDx bombs, how will STD tests help that?
Besides cost, I'm still to get a satisfactory explanation why basics like BSL and Hb aren't immediately added to LDX POC range.
There's no clear plan, is what I'm saying.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.001(3.70%) |
Mkt cap ! $19.46M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.6¢ | 2.6¢ | $3.617K | 139.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 251316 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 697354 | 2 |
View Market Depth
| Last trade - 15.59pm 27/06/2025 (20 minute delay) ? |
| LDX (ASX) Chart |